Announcement

On 18 September 2024, NMIN spin-off company NanoVation Therapeutics (NTx) announced its entry into a multi-target partnership with Denmark-based global healthcare company Novo Nordisk. The multi-year partnership aims to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The approach will combine NTx’ proprietary long-circulating lipid nanoparticle… Read More »NMIN spin-off NanoVation Therapeutics partners with Novo Nordisk

On 6 May 2024, the Government of Canada announced Stage 2 of its integrated Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF) investments in the amount of $574 million for 19 projects at 14 research institutions across Canada. These investments, channelled through five national research hubs—located at… Read More »Funding released to national biomanufacturing hubs involving NMIN researchers & infrastructure

In July 2023, NMIN researcher Dr. Gang Zheng co-founded the new biotechnology company Nanogenix, NMIN’s seventh spin-off company. The company’s novel photo-immune therapy platform, based on the porphysome technology discovered by Dr. Zheng and developed in his lab, aims to change treatment prospects for cancer patients, with an initial focus… Read More »Dr. Gang Zheng co-founds NMIN’s 7th spin-off company

The Board of Directors of the NanoMedicines Innovation Network (NMIN), a national Networks of Centres of Excellence (NCE) funded by the Government of Canada, has appointed Dr. Gilbert Walker Scientific Director & CEO, effective 14 September 2022. Dr. Walker is a Distinguished Professor in the Department of Chemistry in the… Read More »NMIN Board of Directors names Dr. Gilbert Walker Scientific Director & CEO

https://youtu.be/4eg6Y8x1JXE?list=PLh7NyssbO61nky9vVCrRsJG9izYAl5VV6Video profile of GGIA Laureate Acuitas A research team assembled in UBC approximately 40 years ago by NMIN’s Founding Scientific Director, Dr. Pieter Cullis, is receiving a 2022 Governor General’s Innovation Award for their work in developing lipid nanoparticle (LNP) systems to deliver cancer drugs to tumours and to enable… Read More »NMIN’s Founding Scientific Director receives Governor General’s Innovation Award

NMIN spin-off company NanoVation Therapeutics™ (NTx) is growing rapidly and is expanding its overseas operations with the launch of its first NanoVation GENErator™ in the UK, based at the Harwell Science and Innovation Campus near Oxford. The Honourable François-Philippe Champagne PC, MP (Minister of Innovation, Science and Industry) visits NanoVation’s… Read More »NMIN spin-off company NanoVation Therapeutics is expanding into UK

Canadian nanomedicine scientist and NMIN founder Dr. Pieter Cullis, together with his Germany and US-based peers Drs Katalin Kariko and Drew Weissman, have been honoured with a 2022 Canada Gairdner International Award for their contributions to the development of COVID-19 messenger RNA (mRNA) vaccines. Dr. Cullis and colleagues at the… Read More »NMIN’s Founding Scientific Director wins 2022 Canada Gairdner International Award

Canadian nanomedicine scientist and NMIN founder Dr. Pieter Cullis, together with his Germany and US-based peers Drs Katalin Kariko and Drew Weissman, have been honoured with the inaugural VinFuture Grand Prize for their contributions to the development of COVID-19 messenger RNA (mRNA) vaccines. Dr. Cullis and colleagues at the University… Read More »NMIN’s Founding Scientific Director wins VinFuture Foundation’s first global sci-tech award